• Guanru Li, Liyun Sun, Yue Qiu, Yaquan Hou, Libo Du, Kaixuan Zhao, Jiali Qian, Jiuli Liu, and Tengfei Ma.
• Department of Dermatology, Beijing Traditional Chinese Medicine Hospital Shunyi Hospital, Shunyi District, Beijing, China.
• Medicine (Baltimore). 2021 Dec 30; 100 (52): e28178e28178.

IntroductionPsoriasis is a common, recurrent, immune skin disease, which seriously affects patients' quality of life. In clinical practice, modified Runji ointment can effectively treat mild-to-moderate psoriasis with blood dryness syndrome, but there is a lack of high-quality evidence-based medical evidence. This trial aims to evaluate the efficacy and safety of nano-modified Runji ointment in the treatment of mild-to-moderate psoriasis with blood dryness syndrome.Methods/DesignThis study will be a randomized double-blind placebo-controlled trial. A total of 80 patients will be recruited and randomly divided into an intervention group (nano-modified Runji ointment group) and a placebo group at a ratio of 1:1. All included patients will receive 8 weeks of nano-modified Runji ointment or placebo ointment respectively, twice a day. The primary outcome will be the change in psoriasis area and disease severity index score at week 8 compared to baseline. The secondary outcomes will be rash area score, pruritus score, Dermatology Life Quality Index score, traditional Chinese medicine symptom score and adverse events.DiscussionThis study may provide high-quality evidence for the efficacy of nano-modified Runji ointment in the treatment of mild to moderate psoriasis with blood dryness syndrome. The results of this study will be published in peer-reviewed journals.Trial RegistrationChiCTR, ChiCTR2000034292. Registered July 1, 2020, https://www.chictr.org.cn/edit.aspx?pid=55884&htm=4.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

15 keywords...

hide…